Experience with apomorphine infusion cartridge in France – evaluation of patient and healthcare team benefits
Objective: To evaluate ‘real-world’ benefits for patients with Parkinson’s disease (PD) and impact on healthcare team practice of the introduction of apomorphine infusion (APO) cartridge…USE OF NIGHT TIME CONTINUOUS SUBCUTANEOUS INFUSION OF APOMORPHINE (NCSAI) IN ADVANCED PARKINSON’S DISEASE: A SERIES OF 37 CASES.
Objective: The aim of this study is to evaluate the feasibility, efficacy and safety of NCSAI administration in patients with Advanced Parkinson disease (APD). Background:…Case report: Parkinsonim with dyskinesia secondary to amyloid angiopathy
Objective: To report a case of parkinsonism secondary to amyloid angiopathy and discuss the pathophysiology and treatment of this entity. Background: Cerebral amyloid angiopathy is…Availability and accessibility of medicines for patients with Parkinson’s disease in Kyrgyzstan
Objective: The aim of the study was to assess the availability and accessibility of medicines for patients with Parkinson’s disease (PD) in Kyrgyzstan. Background: After…Do Parkinson’s disease medications have an effect on gut microbiome? A case-control study
Objective: To investigate the difference in the gut microbiota between drug-naïve and medicated PD patients and focus on the association between gut microbiota and anti-PD medications. Background:…A neurophysiological profile associated with impulse control disorders in Parkinson’s disease
Objective: To get new insights into the role of oscillatory brain activity recorded non-invasively in patients with Parkinson’s disease (PD) and impulse control disorders (ICDs).…Brain SPECT in Patients with Akinetic-Rigid Syndrome Secondary to Radiotherapy
Objective: The aim of this study is to evaluate the results of brain single photon emission computed tomography (SPECT) with 123-iodine ioflupane in patients with brain…Direct Costs of patients with Parkinson’s Disease in a region of the Brazilian Amazon
Objective: To evaluate the perception of the annual direct costs (medications, medical appointments, rehabilitation, transportation) associated with the treatment for patients with PD in the…Limitations of conventional dopaminergic medication in advanced Parkinson’s disease: results from 127 patients treated with Levodopa Carbidopa Intestinal Gel
Objective: To evaluate the characteristics of the last conventional dopaminergic treatments in a large cohort of patients with advanced Parkinson’s Disease (APD) treated with Levodopa…Motor and non-motor effects of mevidalen in Lewy Body Dementia as measured by the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
Objective: To assess the motor and non-motor effects of mevidalen in patients with Lewy Body Dementia (LBD) as measured by the MDS-UPDRS. Background: Mevidalen is…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 13
- Next Page »